Publicaciones en colaboración con investigadores/as de Complejo Asistencial Universitario de Burgos (41)

2026

  1. Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU

    Therapeutic Advances in Gastroenterology, Vol. 19

  2. CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry

    Hematological Oncology, Vol. 44, Núm. 1

  3. Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 1, pp. 58-73

  4. Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohort

    AIDS, Vol. Publish Ahead of Print

  5. Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort

    AIDS (London, England), Vol. 40, Núm. 4, pp. 414-427

  6. Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

    Blood Cancer Journal

  7. Influence of the level of education on cognitive function in Parkinson’s disease

    Journal of Neural Transmission, Vol. 133, Núm. 4, pp. 663-681

  8. Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort

    HIV Medicine, Vol. 27, Núm. 5, pp. 690-709

  9. Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study

    Journal of Clinical Oncology

  10. Recurrence factors in familial papillary thyroid carcinoma

    Minerva endocrinology, Vol. 51, Núm. 1, pp. 4-16

  11. Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia

    HemaSphere, Vol. 10, Núm. 3

2025

  1. A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

    Journal of Antimicrobial Chemotherapy, Vol. 80, Núm. 12, pp. 3438-3451

  2. Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience

    Transplantation and Cellular Therapy, Vol. 31, Núm. 5, pp. 299.e1-299.e14

  3. Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study

    BMC infectious diseases, Vol. 25, Núm. 1, pp. 944

  4. Correction to: Heterogeneity of cognitive progression and clinical predictors in Parkinson’s disease–subjective cognitive decline (Journal of Neurology, (2025), 272, 3, (246), 10.1007/s00415-024-12808-0)

    Journal of Neurology

  5. Dalbavancin as Suppressive Therapy for Implant-Associated Osteoarticular Infections

    Antibiotics, Vol. 14, Núm. 11

  6. Device-aided therapies (DATs) in Parkinson's disease (PD). The DATs-PD GETM Spanish Registry Protocol Study

    PLoS ONE, Vol. 20, Núm. 3 March

  7. Diagnosis and Treatment of Pulmonary Embolism and Pulmonary Hypertension in Patients With Interstitial Lung Disease

    Open Respiratory Archives, Vol. 7, Núm. 1

  8. Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry

    Journal of Clinical Endocrinology and Metabolism, Vol. 110, Núm. 11, pp. 3155-3167

  9. Dysphagia in Parkinson´s disease. A 5-year follow-up study

    Neurological Sciences, Vol. 46, Núm. 6, pp. 2637-2653